Floatz logo

CABAZITAXEL

Circulating Tumor Cell

Erasmus Medical CenterSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Circulating Tumor Cell cohort.

Asset / SponsorPhaseRating
Piritramide
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4BB
NEPENTHE
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4BB
Capecitabine
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3B
Eloxatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3B
TRASTUZUMAB
AC Camargo Cancer Center
Phase 2CCC

View all 12 →

Same molecule, other indications

CABAZITAXEL is also rated in:

metastatic prostate carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
66 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →